Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice

A syngeneic mouse model bearing a transplanted tumor is indispensable for the evaluation of the efficacy of immune checkpoint inhibitors (ICIs). However, few syngeneic mouse models of liver cancer are available. We established liver tumor cell lines (MHCF1 and MHCF5) from hepatitis C virus transgenic mice fed an atherogenic high-fat diet. MHCF1 and MHCF5 were successfully transplanted into the subcutaneous space of syngeneic C57BL/6 mice, in addition, they efficiently developed orthotopic tumors in the liver of syngeneic C57BL/6 mice. MHCF5 grew rapidly and showed a more malignant phenotype compared with MHCF1. Histologically, MHCF1-derived tumors were a combined type of hepatocellular carcinoma and MHCF5-derived tumors showed a sarcomatous morphology. Interestingly, MHCF1 and MHCF5 showed different sensitivity against an anti-PD1 antibody and MHCF5-derived tumors were resistant to this antibody. CD8 T cells infiltrated the MHCF1-derived tumors, but no CD8 T cells were found within the MHCF5-derived tumors. Gene expression profiling and whole-exon sequencing revealed that MHCF5 displayed the features of an activated cancer stem cell-like signature of sonic hedgehog and Wnt signaling. Therefore, these cell lines could be useful for the identification of new biomarkers and molecular mechanisms of ICI resistance and the development of new drugs against liver cancer.

Graphene-Oxide Based Fluorescent DNA Aptasensor for Liver Cancer Diagnosis and Therapy

Graphene-oxide based fluorescent DNA aptasensors for the <i>in vivo </i>application remain a challenging task. We demonstrate for the first time such a nanomaterial for <i>in vivo</i> diagnosis and therapy of liver tumor with good biocompatibility and high selectivity. This DNA nanomaterial comprising of DNA tetrahedron and aptamers, aggregation-induced emission luminogen (AIEgens) and antitumor drug doxorubicin, is fabricated and attached on GO surface. Additionally, this GO-based fluorescent DNA nanodevice is also constructed by using microfluidic chip for liver tumor cell screening.

Graphene-Oxide Based Fluorescent DNA Aptasensor for Liver Cancer Diagnosis and Therapy

Graphene-oxide based fluorescent DNA aptasensors for the <i>in vivo </i>application remain a challenging task. We demonstrate for the first time such a nanomaterial for <i>in vivo</i> diagnosis and therapy of liver tumor with good biocompatibility and high selectivity. This DNA nanomaterial comprising of DNA tetrahedron and aptamers, aggregation-induced emission luminogen (AIEgens) and antitumor drug doxorubicin, is fabricated and attached on GO surface. Additionally, this GO-based fluorescent DNA nanodevice is also constructed by using microfluidic chip for liver tumor cell screening.

Crystal Structure and Biological Evaluation of Two Novel Organic-Inorganic Hybrid Materials as Antitumor Agents in the Treatment of Liver Cancer

Two novel organic-inorganic hybrid materials {(Hbiz)6[AsIII2AsVMoVI18O62]}·H2O (1, biz = benzimidazole) and (dim)[AsIII2AsVMoVI18O62] [2, dim = 1,6-bis(imidazol)hexane] have been successfully obtained by using the molybdenum arsenate and different N donor organic compounds and determined through X-ray single-crystal diffraction technique. The in vitro cytotoxicity of compounds 1 and 2 was then investigated against three human liver tumor cell lines (SMMC7721, Bel-7402, and MHCC97) by MTT assay. It was found that the two compounds showed potent use as antitumor agents against the aforementioned cell lines.